Dr. Kuerer on De-Escalating Surgery in the Treatment of Patients With Breast Cancer

Video

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses de-escalating surgery in the treatment of patients with breast cancer.

Kuerer believes this research has the potential to be significantly transformative, as women with invasive breast cancer may be able to completely avoid surgery as they undergo treatment.

He goes on to discuss the Feasibility Trial1, which is currently looking to see if oncologists can predict which patients will have no residual disease without breast surgery. As of now, the trial has sustained outstanding results, and these preliminary analyses will contribute to future lines of research in this area.

Reference

1. Kuerer HM. MD Anderson Cancer Center Feasibility Trial for Eliminating Breast Cancer Surgery in Exceptional Responders. Paper presented at: 15th Annual International Congress on the Future of Breast Cancer; July 22, 2016; New York, NY.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD